Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., has announced that it will host an investor presentation on October 21, 2026, at 9 a.m. EDT to showcase its proprietary novel serotonergic agonists (NSAs) for depression and anxiety. The event will focus on HLP003, which is in Phase 3 development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, which is in Phase 2 development for generalized anxiety disorder. The presentation will also include perspectives from key opinion leaders on the evolving treatment landscape, followed by a question-and-answer session with company executives. A live webcast will be accessible through the company's website, with a replay available afterward. Full details are available in the full press release.
The significance of this announcement lies in the urgent unmet need for better treatments for depression and anxiety, two of the most prevalent and debilitating mental health conditions worldwide. Existing therapies often fail to provide durable relief for many patients, and the introduction of NSAs—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity—could represent a new class of treatment. HLP003's Breakthrough Therapy Designation signals that the FDA recognizes the potential for substantial improvement over available options for major depressive disorder, a condition affecting millions. If successful in late-stage trials, HLP003 could offer a much-needed adjunctive option for patients who do not respond adequately to standard antidepressants. Meanwhile, HLP004's Phase 2 progress in generalized anxiety disorder suggests Helus Pharma is pursuing a broad mental health strategy. The investor event is therefore a critical opportunity for shareholders and potential investors to assess the company's clinical momentum, leadership in the NSA space, and the commercial prospects of its pipeline.
Helus Pharma, founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland, and is committed to helping minds heal by developing proprietary NSAs. Its extensive research portfolio includes additional investigational NSAs. For more information, visit the company's website at www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at Helus Pharma.
This article is disseminated on behalf of Helus Pharma and may include paid advertising. BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform provides access to a vast network of wire solutions via InvestorWire and offers editorial syndication to 5,000+ outlets, ensuring maximum reach and impact for news that matters in the life sciences industry.
